title: Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
abstract: OBJECTIVE-To evaluate the antitumor activity and toxic effects of deracoxib, a selective cyclooxygenase-2 inhibitor, in dogs with transitional cell carcinoma (TCC) of the urinary bladder. DESIGN-Clinical trial. Animals-26 client-owned dogs with naturally occurring, histologically confirmed, measurableTCC of the urinary bladder. PROCEDURES-Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. RESULTS-Of 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively. CONCLUSIONS AND CLINICAL RELEVANCE-Results indicated that deracoxib was generally well tolerated by dogs and had antitumor activity against TCC.
authors: Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.
authors: Sarah K
authors: SK
authors: McMillan
authors: Pedro
authors: P
authors: Boria
authors: George E
authors: GE
authors: Moore
authors: William R
authors: WR
authors: Widmer
authors: Patty L
authors: PL
authors: Bonney
authors: Deborah W
authors: DW
authors: Knapp
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053099:Azotemia / Q000139:chemically induced / Q000662:veterinary; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000662:veterinary*; D056486:Chemical and Drug Induced Liver Injury / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008297:Male; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D000096926:Benzenesulfonamides
chemical_list: D000970:Antineoplastic Agents; D013449:Sulfonamides; C471996:deracoxib; D000096926:Benzenesulfonamides